Literature DB >> 16324714

Inhibition of papillomavirus protein function in cervical cancer cells by intrabody targeting.

Heather Griffin1, Robert Elston, Deborah Jackson, Keith Ansell, Michael Coleman, Greg Winter, John Doorbar.   

Abstract

Papillomaviruses (HPVs) are a major cause of human disease, and are responsible for approximately half a million cases of cervical cancer each year. HPVs also cause genital warts, and are the most common sexually transmitted disease in many countries. Despite their importance, there are currently no specific antivirals that are active against HPVs. Papillomavirus protein function is mediated largely by protein-protein interactions, which are difficult to inhibit using conventional approaches. To circumvent these problems, we have prepared an scFv library, and have used this to isolate high-affinity binding molecules that may stearically hinder the association of E6 with p53 and prevent E6-mediated p53 degradation in cervical cancer cells. One of the molecules isolated from the library (GTE6-1), had an affinity for 16E6 of 60nM, and bound within the first zinc finger of the protein. GTE6-1 was able to associate with non-denatured E6 following expression in mammalian cells and could inhibit E6-mediated p53 degradation in in vitro assays. E6-mediated p53 degradation is essential for the continuous growth of cervical cancer cells caused by HPV16. To examine the potential of GTE6-1 as an inhibitor of E6 function in such cells, the molecule was expressed in scFv, diabody and triabody formats in a number of cell lines that are driven to proliferate by the HPV16 oncogenes E6 and E7, including the cervical cancer cell line SiHa. In contrast to small E6-binding peptides containing the ELLG E6-binding motif, GTE6-1 expression lead to changes in nuclear structure, the appearance of apoptosis markers, and an elevation in the levels of p53. No effects were seen with a control scFv molecule, or when GTE6-1 was expressed in cells that are driven to proliferate by simian virus 40 (SV40) T-antigen. Given the accessibility of HPV-associated lesions to topical therapy, our results suggest that large interfering molecules such as intrabodies may be useful inhibitors of viral protein-protein interactions and be particularly appropriate for the treatment of HPV-associated disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16324714     DOI: 10.1016/j.jmb.2005.10.077

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  18 in total

1.  A novel peptide motif binding to and blocking the intracellular activity of the human papillomavirus E6 oncoprotein.

Authors:  Susanne Dymalla; Martin Scheffner; Elvira Weber; Peter Sehr; Claudia Lohrey; Felix Hoppe-Seyler; Karin Hoppe-Seyler
Journal:  J Mol Med (Berl)       Date:  2008-12-21       Impact factor: 4.599

2.  The interaction between human papillomavirus type 16 and FADD is mediated by a novel E6 binding domain.

Authors:  Sandy S Tungteakkhun; Maria Filippova; Jonathan W Neidigh; Nadja Fodor; Penelope J Duerksen-Hughes
Journal:  J Virol       Date:  2008-07-16       Impact factor: 5.103

3.  Identification and characterization of small molecule antagonists of pRb inactivation by viral oncoproteins.

Authors:  Daniela Fera; David C Schultz; Santosh Hodawadekar; Melvin Reichman; Preston Scott Donover; Jason Melvin; Scott Troutman; Joseph L Kissil; Donna M Huryn; Ronen Marmorstein
Journal:  Chem Biol       Date:  2012-04-20

4.  Retinoblastoma-independent antiproliferative activity of novel intracellular antibodies against the E7 oncoprotein in HPV 16-positive cells.

Authors:  Luisa Accardi; Maria Gabriella Donà; Anna M Mileo; Marco G Paggi; Antonio Federico; Paola Torreri; Tamara C Petrucci; Rosita Accardi; David Pim; Massimo Tommasino; Lawrence Banks; Barbara Chirullo; Colomba Giorgi
Journal:  BMC Cancer       Date:  2011-01-17       Impact factor: 4.430

Review 5.  Recent Progress in Therapeutic Treatments and Screening Strategies for the Prevention and Treatment of HPV-Associated Head and Neck Cancer.

Authors:  Sonia N Whang; Maria Filippova; Penelope Duerksen-Hughes
Journal:  Viruses       Date:  2015-09-17       Impact factor: 5.048

6.  In-cell intrabody selection from a diverse human library identifies C12orf4 protein as a new player in rodent mast cell degranulation.

Authors:  Elsa Mazuc; Laurence Guglielmi; Nicole Bec; Vincent Parez; Chang S Hahn; Caroline Mollevi; Hugues Parrinello; Jean-Pierre Desvignes; Christian Larroque; Ray Jupp; Piona Dariavach; Pierre Martineau
Journal:  PLoS One       Date:  2014-08-14       Impact factor: 3.240

Review 7.  PPI Modulators of E6 as Potential Targeted Therapeutics for Cervical Cancer: Progress and Challenges in Targeting E6.

Authors:  Lennox Chitsike; Penelope J Duerksen-Hughes
Journal:  Molecules       Date:  2021-05-18       Impact factor: 4.411

Review 8.  Cellular binding partners of the human papillomavirus E6 protein.

Authors:  Sandy S Tungteakkhun; Penelope J Duerksen-Hughes
Journal:  Arch Virol       Date:  2008-01-03       Impact factor: 2.574

9.  Intracellular Analysis of the Interaction between the Human Papillomavirus Type 16 E6 Oncoprotein and Inhibitory Peptides.

Authors:  Christina Stutz; Eileen Reinz; Anja Honegger; Julia Bulkescher; Johannes Schweizer; Katia Zanier; Gilles Travé; Claudia Lohrey; Karin Hoppe-Seyler; Felix Hoppe-Seyler
Journal:  PLoS One       Date:  2015-07-07       Impact factor: 3.240

Review 10.  Immunologic treatments for precancerous lesions and uterine cervical cancer.

Authors:  Patrizia Vici; Luciano Mariani; Laura Pizzuti; Domenico Sergi; Luigi Di Lauro; Enrico Vizza; Federica Tomao; Silverio Tomao; Claudia Cavallotti; Francesca Paolini; Aldo Venuti
Journal:  J Exp Clin Cancer Res       Date:  2014-03-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.